Literature DB >> 16548904

Mechanisms by which systemic salbutamol increases ventilation.

Antony E Tobin1, Anne-Marie Pellizzer, John D Santamaria.   

Abstract

BACKGROUND AND
OBJECTIVE: Salbutamol (SAL) has systemic effects that may adversely influence ventilation in asthmatic patients. The authors sought to determine the magnitude of this effect and mechanisms by which i.v. SAL affects ventilation.
METHODS: A prospective study of nine healthy subjects (eight men, one woman; age 23 +/- 1.4 years (SD)) was undertaken. Each subject received i.v. SAL at 5, 10 and 20 microg/min each for 30 min at each dose and was observed for 1 h post infusion. Minute ventilation ((VE)), oxygen consumption (VO(2)), CO(2) production (VCO(2)), occlusion pressure (P(0.1)), heart rate, blood pressure, respiratory rate, glucose, arterial blood gases, lactate and potassium (K(+)) were recorded at baseline and at 30-min intervals. The effect of 100% oxygen on (VE) and P(0.1) during SAL infusion at 20 microg/min was observed. Results are expressed as mean +/- SEM.
RESULTS: V(E) was significantly increased at 20 microg/min SAL (37.8 +/- 12.1%, P = 0.01), as were VO(2) (22.5 +/- 5.1%, P < 0.01) and VCO(2) (40.9 +/- 10.6%, P < 0.01). Ventilation was in excess of metabolic needs as demonstrated by a rise in the respiratory exchange ratio (0.87 +/- 0.03 to 0.99 +/- 0.04, P < 0.05). Serum lactate rose by 124 +/- 30.4% from baseline to 20 microg/min (1.1 +/- 0.1 to 2.3 +/- 0.25 mmol/L, P < 0.01) and base excess decreased (0.89 +/- 0.56 to vs. -1.75 +/- 0.52 mmol/L, P < 0.01) consistent with a lactic acidosis contributing to the excess ventilation. There was no significant differences in (VE) or P(0.1) with F(I)O(2) = 1.0, suggesting peripheral chemoreceptor stimulation was not responsible for the rise in (VE). At 20 microg/min SAL, K(+) fell significantly from baseline (3.8 +/- 0.06 to 2.8 +/- 0.09 mmol/L, P < 0.001).
CONCLUSION: Systemic SAL imposes ventilatory demands by increasing metabolic rate and serum lactate. This may adversely affect patients with severe asthma with limited ventilatory reserve.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16548904     DOI: 10.1111/j.1440-1843.2006.00832.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

1.  Treating acute asthma--salbutamol may not always be the right answer.

Authors:  Sharon Sturney; Jay Suntharalingam
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

Review 2.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

3.  Salbutamol effects on systemic potassium dynamics during and following intense continuous and intermittent exercise.

Authors:  Muath M Altarawneh; Aaron Petersen; Robert Smith; David M Rouffet; Francois Billaut; Ben D Perry; Victoria L Wyckelsma; Antony Tobin; Michael J McKenna
Journal:  Eur J Appl Physiol       Date:  2016-10-22       Impact factor: 3.078

4.  Effects of β2-adrenergic stimulation on exercise capacity in normal subjects.

Authors:  S P Beloka; C Janssen; E Woff; E Brassine; G Deboeck; J Randria; V Philippart de Foy; P van de Borne; R Naeije
Journal:  Eur J Appl Physiol       Date:  2011-02-16       Impact factor: 3.078

5.  Exercise performance after salbutamol inhalation in non-asthmatic, non-athlete individuals: a randomised, controlled, cross-over trial.

Authors:  Filip Eckerström; Christian Emil Rex; Marie Maagaard; Sune Rubak; Vibeke Elisabeth Hjortdal; Johan Heiberg
Journal:  BMJ Open Sport Exerc Med       Date:  2018-08-30

Review 6.  Respirology year-in-review 2006: clinical science.

Authors:  Y C Gary Lee; Richard Beasley
Journal:  Respirology       Date:  2007-01       Impact factor: 6.424

7.  A case of lactic acidosis complicating assessment and management of asthma.

Authors:  Tonny V Veenith; Abigail Pearce
Journal:  Int Arch Med       Date:  2008-04-15

8.  Prevalence and risk factors of lactic acidosis in children with acute moderate and severe asthma, a prospective observational study.

Authors:  Marta Ruman-Colombier; Isabelle Rochat Guignard; Ermindo R Di Paolo; Mario Gehri; Jean-Yves Pauchard
Journal:  Eur J Pediatr       Date:  2020-10-22       Impact factor: 3.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.